American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...

A new survey has shown which companies in Denmark are trusted the most and least. Novo Nordisk is at the top, followed by ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Approval Drop. In this article, we ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift ...

Novo Nordisk is growing its India-based global business services to fill out vertical stacks, expand horizontal functions, ...

Novo Nordisk, the Danish pharmaceutical giant, has filed a lawsuit against Singapore-based KBP Biosciences and its founder, ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...